Hospital

The best protection against all variants of COVID-19 continues to be vaccination, including a booster shot for eligible individuals.

These benefits included increased survival, a lower risk of hospital readmission for heart failure, and an overall improvement in quality of life.

The investigators note that this is the largest annual decrease in 2 decades of reporting.

Approximately half of people with HCV don't know they're infected, mainly because they have no symptoms.

Officials with the FDA have approved the QuantiFERON-TB Gold Plus assay for use on DiaSorin’s automated LIAISON XS platform.

Investigators have developed an antibody-based treatment for Alzheimer disease, as well as a protein-based vaccine.

Further, at daily doses of at least 100 mg, the rates of VTE with milvexian were significantly lower than with enoxaparin, according to the study authors.

The team found that out of more than 18,751 live births, 1008 cancer diagnoses were made in offspring 0 to 58 years of age.

Chronic HBV increases the risk of developing liver failure, liver cancer, and cirrhosis.

Ray Tancredi, RPh, MBA, divisional VP of specialty pharmacy development and brand Rx/vaccine purchasing at Walgreens, provides an analysis and overview of key specialty pharmaceuticals in development.

The odds of visiting an ED for anxiety were 2.8 times greater than for non-depressed individuals.

The device is to be worn on the stomach and senses when an individual stops breathing and moving, followed by an injection of naloxone that can restore respiration.

Ismail Lourido Ali, the director and counsel of policy and advocacy at the Multidisciplinary Association for Psychedelic Studies (MAPS), discusses continuing education opportunities for pharmacists to get trained on the proper use and administration of psychedelic drugs.

Ron Aung-Din, MD, the clinical medical advisor of Pyscheceutical, and Chad Harman, the CEO of Pyscheceutical, discuss a novel approach for administering psychedelics for the treatment of brain disorders that does not induce hallucinogenic effects.

IVIG also has an important therapeutic role in cases with multisystem inflammatory syndrome in children (MIS-C), the researchers said.

These results are based on a case report of a patient with LCV associated to sensitive neuropathy for whom systemic treatment was ineffective.

The investigators said that this analysis is the most comprehensive assessment of vaccination rates among US hospital personnel to date, using data from 3.3 million HCP.

According to the researchers, almost half of the caregivers surveyed responded that the people they are caring for rely on them more than ever before, with 94% of respondents indicating that they put the needs of the person they care for above their own during the COVID-19 pandemic.

Diagnosis, treatment options, and the role of the pharmacist in patient care are all important factors when looking at multiple sclerosis as a whole.

Ray Tancredi, RPh, MBA, divisional VP of specialty pharmacy development and brand Rx/vaccine purchasing at Walgreens, discusses key drugs in development that are slated to launch in 2022.

Sotrovimab found not inferior to intravenous administration for the early treatment of mild-to-moderate COVID-19 in high-risk, non-hospitalized patients 12 years of age and older.

No differences found in all-cause mortality or stroke between patients with aortic stenosis at intermediate surgical risk who had transcatheter aortic valve replacement or surgery.

Besermi is an interferon alfa-2b indicated for the treatment of adults with polycythemia vera.

Ocrelizumab is indicated for the treatment of relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting MS, and active secondary progressive disease, in adults.

The results showed that one 300 mg dose of AZD7442 reduced the risk of developing symptomatic COVID-19 by 83% and one 600 mg dose reduced the risk of developing severe COVID-19 or death (from any cause) by 88% compared to the placebo.

The FDA has approved maribavir for the treatment of adults and pediatric patients aged 12 years or older and weighing at least 35 kg with post-transplant cytomegalovirus infection/disease that is refractory to treatment with ganciclovir, valganciclovir, cidofovir, or foscarnet.